Trial reportHypertension research : official journal of the Japanese Society of Hypertension2017
Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia.
Trial report in Hypertension research : official journal of the Japanese Society of Hypertension, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Comparison of the efficacy and safety of benzbromarone and febuxostat in gout and hyperuricemia: a systematic review and meta-analysis.Clinical rheumatology · 2024Pooled it
- Pharmacotherapy for hyperuricaemia in hypertensive patients.The Cochrane database of systematic reviews · 2020Pooled it
- Superiority of Low-Dose Benzbromarone Add-On to Low-Dose Febuxostat Compared With Febuxostat Monotherapy in Gout With Combined-Type Hyperuricemia.Arthritis care & research · 2024Trial
- Acute effects of hypouricemia on endothelium, oxidative stress, and arterial stiffness: A randomized, double-blind, crossover study.Physiological reports · 2021Trial
- Urate-lowering therapy modifies associations between urinary urate and kidney outcome.Renal failure · 2026Article
- Therapeutic Strategies for Hyperuricemia: From Small-Molecule Inhibitors to RNA Therapeutics.ACS pharmacology & translational science · 2026Review
- Association of ABCG2 gene variants with urate levels in Mexican patients with type 2 diabetes and chronic kidney disease.Scientific reports · 2026Article
- Review
- [Diagnostics and treatment of gout : Short version of the German S3 guideline].Zeitschrift fur Rheumatologie · 2025Review
- Gender-specific association between serum uric acid levels and hypertension in East China: a cross-sectional study.BMC public health · 2025Article
- Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision).Journal of geriatric cardiology : JGC · 2025Article
- The efficacy of a low-dose combination of febuxostat and benzbromarone versus each drug used alone for the treatment of gout.Frontiers in medicine · 2025Article
- The role of uric acid in the risk of hypertension developed from prehypertension: a five-year Chinese urban cohort study.Archives of public health = Archives belges de sante publique · 2024Article
- The potential relationship of coronary artery disease and hyperuricemia: A cardiometabolic risk factor.Heliyon · 2023Review
- The association among uric acid, microalbumin and estimated glomerular filtration rate in hypertensive patients: a case control study.BMC cardiovascular disorders · 2023Article
- Association of serum xanthine oxidase levels with hypertension: a study on Bangladeshi adults.Scientific reports · 2022Article
- Which is more important, xanthine oxidase activity or uric acid itself, in the risk for cardiovascular disease?Hypertension research : official journal of the Japanese Society of Hypertension · 2021Article
- Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 health examination registry.Scientific reports · 2020Article
- Higher baseline uric acid concentration is associated with non-attainment of optimal blood pressure.PloS one · 2020Article
- The effects of topiroxostat on vascular function in patients with hyperuricemia.Journal of clinical hypertension (Greenwich, Conn.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uric acid (UA) has been associated with hypertension, renal disease and cardiovascular disease. The aim of the present study was to compare the UA-lowering effects of a standard dose of the UA synthesis inhibitor febuxostat to a standard dose of the uricosuric agent benzbromarone, and to investigate the effects of a low-dose combination of both agents in hypertensive patients with hyperuricemia. Twenty hypertensive patients with inadequate UA control were administered febuxostat 40 mg (Feb), benzbromarone 50 mg (Ben) and febuxostat 20 mg and benzbromarone 25 mg (feb/ben) for 3 months each in a randomized modified crossover manner. UA metabolism, blood pressure (BP) and the indices of organ damage were assessed at baseline and the end of each treatment period. No significant changes were observed in BP or estimated glomerular filtration rate (eGFR) after the treatment with each UA-lowering regimen. The change in UA was significantly greater with feb/ben than with Feb. The excretion of UA and clearance of UA were higher with Ben than with Feb and feb/ben. Urinary 8-hydroxydeoxyguanosine and liver-type fatty-acid-binding protein levels were slightly lower with Ben, whereas flow-mediated dilation was slightly higher with feb/ben and Ben. The UA-lowering effects of the low-dose combination of the UA synthesis inhibitor and uricosuric agent were greater than those of the standard dose of each agent alone. The uricosuric agent may be more effective at improving vascular function than the UA synthesis inhibitor. Thus, the appropriate management of hyperuricemia with uricosuric drugs appears to be useful for hypertensive patients with hyperuricemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.